LifeMD Appoints William J. Febbo to its Board of Directors
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today...
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today...
SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced the publication in Cancers of a peer-reviewed...
Fort Lee, NJ , June 20, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a...
Single Agent Envafolimab ORR Exceeded Futility Rule that will be Applied at the Interim Efficacy Analysis Expected in Q3 Continuing...
SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases,...
–Grant supports the continued preclinical development of AX-5006, a small molecule, gut-restricted amyloid inhibitor for symptomatic treatment and modification of...
LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain INPEFA recently approved for treatment of heart failure THE...
- Phase 2 topline interim results expected in 1Q 2024 - - 6-month durability data for Phase 1 trial of IVX-A12...
- First Presentation of Data From Phase 3 ASCEND Study Will Feature Pharmacokinetic Results That Indicate Minimal Systemic Absorption of...
Media Release SYDNEY, AUSTRALIA, June 20, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company...
Tigris trial enrollment at 64 patients Crude mortality results continue to exceed expectations TORONTO, June 20, 2023 (GLOBE NEWSWIRE) --...
Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance, Strategy and Risk Governance NEW...
LPAD may provide alternative pathways for streamlined product approvalLOS GATOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc....
Oak Ridge, TN, June 20, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement...
Additional Time Needed for Labeling and Post-Marketing Requirements Discussions; PDUFA Date Set for September 19, 2023SAN DIEGO, June 20, 2023...
PURCHASE, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that...
CINCINNATI, June 20, 2023 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based...
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
- Treatment with infigratinib at the Cohort 5 dose level resulted in a significant and robust increase in annual height...
INV501, a potentially first-in-class compound, induces strong anti-tumor immune responses in preclinical models in different solid tumor indicationsTreatment with INV501...